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OBJECTIVES: The recent PREDICTIVE (Predictable Results
and Experience in Diabetes through Intensiﬁcation and Control
to Target: an International Variability Evaluation) clinical trial
demonstrated that switching type 2 diabetes patients on human
soluble insulin (HSI) to insulin aspart (IAsp, NovoRapid) was
associated with improvements in HbA1c and body weight. The
aim of this study was to assess the long-term clinical implications
of these beneﬁts in type 2 diabetes patients in the Polish setting.
METHODS: A previously published and validated computer
simulation model of diabetes was used to project long-term clini-
cal outcomes associated with these two treatments based on
published data. Short-term treatment effects were taken from the
PREDICTIVE study. Baseline cohort characteristics were based
on PREDICTIVE and supplemented with published data consid-
ered to be representative of Polish type 2 diabetes patients.
RESULTS: Treatment with IAsp was projected to increase undis-
counted life expectancy by approximately 0.05 years compared
to HSI (6.91  0.12 versus 6.86  0.12 years). Applying an
annual discount rate of 5% decreased this beneﬁt to 0.03 years
(5.12  0.12 versus 5.09  0.12 years). Treatment with IAsp
was projected to decrease the incidence of retinopathy, cardio-
vascular and renal complications compared to HSI. For example,
the cumulative incidence (CI) of myocardial infarction was
reduced by 4.5% with IAsp compared to HSI. Similarly, reduc-
tions in CI of proliferative diabetic retinopathy (17.6%), neur-
opathy (8.4%) and overt nephropathy (12.4%) were projected.
The CI of end-stage renal disease, one of the costliest complica-
tions of diabetes, was reduced by 14.5% with IAsp compared to
HSI. CONCLUSION: Over patient lifetimes, IAsp treatment was
projected to result in fewer diabetes-related complications and
improve life expectancy. In a population with a relatively high
baseline prevalence of complications considered to be represen-
tative of Polish type 2 diabetes patients, IAsp-based therapy was
projected to reduce the development of complications compared
to HSI.
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OBJECTIVES: Most of the available disease models are “black
box” software. Even with published methods and structure,
users are in most cases not able to proof how a model really
works. Mislead intellectual property concerns and powerful
interests behind disease models are leading to substantial criti-
cism in terms of quality and credibility [1]. The PROSIT
Disease Modelling Community aims at developing open source
disease models for the ﬁve most important late complications
of type 2 diabetes mellitus until 2010. In the long run an
electronic library of freely available disease models is being
established in the internet. METHODS: The PROSIT Commu-
nity was founded and went online in June 2006 (http://
forum.prosit.de). Since March 2007 the project is hosted at
Heilbronn University. Disease models are being developed as
stochastic Markov processes using the open source spreadsheet
software OpenOfﬁce Calc. All models are licensed under the
GNU Public License. For communication and as working envi-
ronment the bulletin board software MyBB 1.1.2 is being used.
In July 2007 the project moves to a Wiki environment. Cur-
rently 41 members are registered of which only a third is par-
ticipating actively. RESULTS: There are development threads
for the countries Germany, Romania and Switzerland. Beta ver-
sions are available for nephropathy and retinopathy. Since May
2007 PROSIT is a reference project for the OpenOfﬁce.org
Community. CONCLUSION: Open source disease modelling
seems to be a new approach. Participants have to develop a
new working process for developing models on a public plat-
form. PROSIT assures: Sustainability: models are available per-
manently to the public. Transparency: the model development
can be checked in the internet. Credibility: a community with
members from currently four European countries develops,
discusses and controls the models. [1] Jefferson T, Demicheli
V. Quality of economic evaluations in health care. BMJ
2002;324:313–4.
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